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Abstract
Objective—Given that non-dialysis dependent chronic kidney disease (NDD-CKD) patients have 
a disproportionately higher prevalence of hypothyroidism compared to their non-CKD 
counterparts, we sought to determine the association between thyroid status, defined by serum 
thyrotropin (TSH) levels, and mortality among a national cohort of NDD-CKD patients.
Patients and Methods—Among 227,422 US veterans with Stage 3 NDD-CKD with ≥1 TSH 
measurement(s) during 10/1/2004-9/30/12, we first examined the association of thyroid status, 
defined by TSH categories of <0.5, 0.5-5.0 (euthyroidism), and >5.0mIU/L, with all-cause 
mortality. We then evaluated six granular TSH categories: <0.1, 0.1-<0.5, 0.5-<3.0, 3.0-5.0, 
>5.0-10.0, >10.0mIU/L. We concurrently examined thyroid status, thyroid-modulating therapy, 
and mortality in sensitivity analyses.
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Results—In expanded case-mix Cox analyses, compared to euthyroidism, baseline and time-
dependent TSH levels >5.0mIU/L were associated with higher mortality (adjusted HRs [aHRs] 
[95%CI] 1.19 [1.15-1.24] and 1.23 [1.19-1.28], respectively), as were baseline and time-dependent 
TSH <0.5mIU/L (aHRs [95%CI] 1.18 [1.15-1.22] and 1.41 [1.37-1.45]). Granular examination of 
thyroid status showed that incrementally higher TSH ≥3.0mIU/L were associated with 
increasingly higher mortality in baseline and time-dependent analyses, and TSH categories 
<0.5mIU/L were associated with higher mortality (reference: 0.5-<3.0mIU/L) in baseline analyses. 
In time-dependent analyses, untreated and undertreated hypothyroidism and untreated 
hyperthyroidism were associated with higher mortality (reference: spontaneous euthyroidism), 
whereas hypothyroidism treated-to-target showed lower mortality.
Conclusion—Among US veterans with NDD-CKD, high-normal TSH (≥3.0mIU/L) and lower 
TSH (<0.5mIU/L) levels were associated with higher death risk. Interventional studies identifying 
the target TSH range associated with the greatest survival in NDD-CKD patients are warranted.
Keywords
Thyroid; thyrotropin; hypothyroidism; mortality; chronic kidney disease
Introduction
Thyroid dysfunction is a highly prevalent yet under-recognized endocrine complication 
affecting a large proportion of chronic kidney disease (CKD) patients.1,2 Several large 
population-based studies show that hypothyroidism is increasingly more common with 
incrementally impaired kidney function.3-7 Data from 14,623 participants in the Third 
National Health and Nutrition Examination Survey has shown that the prevalence of 
hypothyroidism was 5.4%, 10.9%, 20.4%, 23.0%, and 23.1% among those with estimated 
glomerular filtration rates (eGFRs) of ≥90, 60-89, 45-59, 30-44, and <30ml/min/1.73m2, 
respectively.5 More recently, among a large national cohort of 461,607 US veterans with 
Stage 3-5 CKD, for every 10ml/min/1.73m2 decrement in eGFR, there was an 18% higher 
likelihood of hypothyroidism.6 While there are comparatively fewer reports in end-stage 
renal disease (ESRD) patients, a similarly high prevalence (~22%) of hypothyroidism has 
been observed in large dialysis cohorts.8,9
In the general population, adverse cardiovascular sequelae may result from untreated 
hypothyroidism (e.g., altered cardiac structure and function, endothelial dysfunction, 
dyslipidemia, accelerated atherosclerosis, electrophysiologic changes10-13) as well as with 
hyperthyroidism (e.g., atrial fibrillation, heart failure, coronary ischemia12,14). Hence, this 
high burden of thyroid dysfunction may have an important bearing upon the survival of 
kidney disease patients, who suffer from disproportionately high cardiovascular death risk 
(~40% of deaths15,16). Indeed, a growing body of evidence shows that hypothyroidism, 
defined by elevated serum thyrotropin (TSH) levels as the most sensitive and specific 
clinical goal standard of thyroid function assessment,17-19 is associated with higher mortality 
in some,8,9,20,21 but not all,22 studies of the dialysis population. Recent data have also 
corroborated a link between hyperthyroidism and sudden cardiac death among hemodialysis 
patients from the Die Deutsche Diabetes Dialyse Studie (4D Trial),22 and with all-cause 
mortality in a national peritoneal dialysis cohort.9 However, little is known about the 
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association between thyroid status and mortality risk in CKD patients who are non-dialysis 
dependent (NDD).
To address this knowledge gap, we conducted a study examining the relationship between 
thyroid status and mortality risk among a large longitudinal cohort of US veterans with 
Stage 3 CKD and repeated measures of serum TSH over time. We hypothesized that both 
higher and lower TSH levels were independently associated with higher mortality risk in this 
nationally representative NDD-CKD cohort. Based on prior studies of thyroid status and 
mortality in the dialysis population,8,20 we were also specifically interested in examining the 
TSH threshold of ≥3.0mIU/L as the level above which higher mortality is observed in NDD-
CKD patients.
Methods
Source Cohort
We conducted a historical cohort study using data from the “Racial and Cardiovascular Risk 
Anomalies in CKD” (RCAV) study, constructed to examine US veterans with incident CKD 
who underwent care within the Veterans Affairs (VA) healthcare system over the period of 
October 1, 2004 to September 30, 2012.23-26 Patients were included provided that they 
underwent at least one TSH measure anytime during the study period; had the requisite 
covariates needed to calculate eGFR (e.g., age, race, serum creatinine) within one year of 
study entry (i.e., date of the baseline TSH); and had Stage 3 CKD (eGFR 30-<60ml/min/
1.73m2) at study entry. Patients were excluded if they were receiving dialysis at the time of 
study entry; had an improbable TSH level (i.e., 0mIU/L); or had an implausible follow-up 
time value. The study was approved by the Institutional Review Committees of the Memphis 
and Tibor Rubin VA Medical Centers.
Exposure Ascertainment
The exposure of interest was thyroid status defined by serum TSH concentration 
(irrespective of treatment status). In primary analyses, we examined thyroid status 
categorized as TSH levels of >5.0, 0.5-5.0, and <0.5mIU/L (based on thresholds used in the 
general population for ascertainment of hypothyroidism, euthyroidism, and hyperthyroidism, 
respectively).8,9,17 In secondary analyses, we examined thyroid status using more granular 
categorizations of TSH, defined according to the usual TSH ranges for these designations: 
overt-hypothyroid (>10.0mIU/L), subclinical-hypothyroid (>5.0-10.0mIU/L), high-normal 
(3.0-5.0mIU/L), low- normal (0.5-<3.0mIU/L), subclinical-hyperthyroid (0.1-<0.5mIU/L), 
and overt-hyperthyroid (<0.1mIU/L) ranges.8,9,20 We were specifically interested in the TSH 
threshold of ≥3.0mIU/L as the level above which higher mortality may be observed.8,20 We 
also examined TSH as a continuous predictor of mortality using restricted cubic spline 
analyses with knots defined at the 33rd and 66th percentiles of observed TSH values.
We first examined the association between baseline thyroid status and all-cause mortality in 
order to ascertain long-term associations of thyroid status with death risk.27 As underlying 
illness may influence serum TSH levels in the absence of true thyroid functional disease 
while also increasing patients’ risk of death, we conducted two types of sensitivity analyses 
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of baseline thyroid status and mortality risk: (1) analyses which included a 30-day lag period 
between the date of baseline TSH measurement and start of follow-up time to minimize bias 
from reverse causation,20 and (2) analyses which examined the association of incident 
hypothyroidism and incident hyperthyroidism (defined as those who had a baseline TSH 
level that was within reference range [0.5-5.0mIU/L] and had second TSH level was 
>5.0mIU/L and <0.5mIU/L, respectively) with mortality.
We then examined the association between time-dependent thyroid status and all-cause 
mortality, in which thyroid status was time-updated with repeated TSH measures in order to 
ascertain short-term associations of thyroid status with death risk, and to account for 
changes in thyroid status over time.27 The median (IQR) and minimum-maximum number 
of TSH measurements contributed by each patient was 4 (2, 6) and 1-54, respectively.
To determine the impact of thyroid-modulating therapy on the association of thyroid status 
with mortality, we compared death risk across the following categories that concurrently 
considered patients’ TSH levels and medication status: hypothyroid overtreated (TSH 
<0.5mIU/L, on thyroid hormone replacement), hypothyroid untreated (TSH >5.0mIU/L, not 
on thyroid hormone replacement), hypothyroid undertreated (TSH >5.0mIU/L, on thyroid 
hormone replacement), hypothyroid treated-to-target (TSH 0.5-5.0mIU/L, on thyroid 
hormone replacement), spontaneously euthyroid (TSH 0.5-5.0mIU/L, not on thyroid 
hormone replacement or anti-thyroid medication), hyperthyroid undertreated (TSH 
<0.5mIU/L, on anti-thyroid medication), hyperthyroid untreated (TSH <0.5mIU/L, not on 
anti-thyroid medication), and hyperthyroid overtreated (TSH >5.0mIU/L, on anti-thyroid 
medication). Serum TSH data were obtained from the Decision Support System National 
Data Extracts (DSS-NDE) Laboratory Results file.28 Medication data were obtained from 
VA pharmacy dispensation records.29
Outcome Ascertainment
Our outcome of interest was all-cause mortality. Patients were followed for outcomes 
starting the day after TSH measurement. Patients were censored for kidney transplantation, 
loss to follow-up, or the last date of available follow-up data (July 26, 2013), whichever 
occurred first. All-cause mortality data, censoring events, and associated dates were obtained 
from VA Vital Status File, which has been observed to have a sensitivity and specificity of 
98.3% and 99.8%, respectively, in comparison to the National Death Index.30
Socio-demographic, Comorbidity, Medication, and Laboratory Covariates
Patients’ baseline socio-demographic information (age, sex, race, ethnicity) was obtained 
from the VA Corporate Data Warehouse and from Medicare through the VA-Medicare data 
merge project31 as previously described.23-26 Information about comorbidities was extracted 
from the VA Inpatient and Outpatient Medical SAS datasets using ICD-9 diagnostic and 
procedure codes and Current Procedural Terminology codes.32 Charlson Comorbidity Index 
(CCI) scores were estimated using the Deyo modification for administrative datasets without 
including kidney disease.33 Body mass index data were obtained from the VA Vital Status 
file. Laboratory data except serum creatinine were obtained from the DSS-NDE Laboratory 
Results files.28 VA Corporate Data Warehouse LabChem data files were used to extract 
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serum creatinine data.34 Using serum creatinine and demographic data, eGFR was calculated 
using the Chronic Kidney Disease Epidemiology Collaboration equation.35
Statistical Analyses
We estimated the association between thyroid status and mortality using Cox proportional 
hazard models with five hierarchical levels of covariate adjustment. In time- dependent 
analyses, all laboratory data were examined as time-dependent covariates:
1. Unadjusted model: Included serum TSH level as the primary exposure of 
interest;
2. Case-mix model: Adjusted for age, sex, race, and ethnicity;
3. Expanded case-mix model: Adjusted for covariates in the case-mix model, as 
well as diabetes, congestive heart failure (CHF), cardiovascular disease (CVD), 
hypertension, hyperlipidemia, and CCI score;
4. Expanded case-mix+laboratory model, also known as adjustment for 
malnutrition- inflammation-cachexia syndrome (MICS) covariates: Adjusted for 
covariates in the expanded case-mix model, as well as eGFR, serum albumin, 
hemoglobin, cholesterol, triglycerides, and low-density lipoprotein (LDL);
5. Expanded case-mix+laboratory+thyroid medication model: Adjusted for 
covariates in the expanded case-mix+laboratory model, as well as thyroid 
hormone supplementation and anti-thyroid medication use.
We a priori defined the expanded case-mix adjusted model as our preferred model, which 
included core socio-demographic measures and other confounders of the association 
between thyroid status and mortality. While there were no missing data for covariates in the 
case-mix and expanded case-mix models (e.g., age, sex, race, ethnicity, comorbidities), there 
were varying degrees of missing data for laboratory variables including albumin (17.3%), 
hemoglobin (15.4%), triglycerides (13.7%), cholesterol (13.6%), and LDL (18.9%; 
proportions shown represent missing baseline data). Hence, further adjustment for potential 
confounders in expanded case-mix+laboratory and expanded case-mix+laboratory+thyroid 
medication models (which have the potential for inherent selection bias due to missing data) 
were conducted as sensitivity analyses. In these analyses, missing data were handled using 
multiple imputation.
To address differential quality of care as a potential confounder of thyroid status—mortality 
associations, we conducted a series of sensitivity analyses that incrementally adjusted for 
proxies of provider attentiveness/adherence with health care recommendations and patient 
medical compliance, in addition to covariates in the expanded case-mix+laboratory+ thyroid 
medication model: (1) Angiotensin converting enzyme inhibitor (ACE-i), angiotensin 
receptor blocker (ARB), or statin prescription within one year of study entry, (2) receipt of 
influenza vaccination within one year of study entry, or (3) patient’s history of non-
compliance with medical treatment ascertained by ICD-9 code V15.81.
We additionally conducted subgroup analyses of thyroid status (categorized as TSH levels 
>5.0, 0.5-5.0 [euthyroid], and <0.5mIU/L) across clinically relevant categories of socio- 
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demographics, comorbidity status, and laboratory measures. Proportional hazards 
assumptions were confirmed by graphical analysis. Analyses and figures were generated 
using SAS version 9.4 (SAS Institute Inc., Cary, NC), Stata version 14 (Stata Corporation, 
College Station, TX), and SigmaPlot Version 12.5 (Systat Software, San Jose, CA).
Results
Study Population
Among 227,426 patients who met eligibility criteria (eFigure 1), 6.4%, 90.0%, and 3.4% of 
patients had baseline TSH levels of >5.0, 0.5-5.0 (euthyroid), and <0.5mIU/L, respectively. 
The mean ± SD, median (IQR), and minimum-maximum of observed baseline TSH values 
were 2.7 ± 6.7, 1.9 (1.2, 2.8), and 0.001-531.5mIU/L, respectively. Compared to patients 
whose baseline TSH levels were <0.5mIU/L or in the euthyroid range, those with TSH levels 
>5.0mIU/L were older, more likely to be non-Hispanic White, and less likely to be non-
Hispanic Black; were more likely to have cardiovascular disease and less likely to have 
hypertension; were more likely to have higher total cholesterol and triglyceride levels; and 
were less likely to be prescribed an ACE-i or ARB within one year of study entry (Table 1). 
Compared to patients who were euthyroid at baseline, those who were hyperthyroid and 
hypothyroid were also more likely to have CHF and less likely to have hyperlipidemia. 
Baseline characteristics of patients categorized by finer gradations of TSH are shown in 
eTable 1.
Thyroid Status and Mortality—Patients contributed a total of 1,134,837 patient-years of 
follow-up during which time 67,706 all-cause deaths occurred. Median (IQR) at-risk time 
was 65 (38, 83) months. In analyses of baseline thyroid status adjusted for expanded case-
mix covariates, TSH levels >5.0 and <0.5mIU/L were each associated with higher mortality 
risk (reference: euthyroidism): adjusted HRs (aHRs) (95%CI) 1.19 (1.15-1.24) and 1.18 
(1.15-1.22), respectively (Figure 1A and eTable 2). These associations were mildly 
attenuated after further adjustment for expanded case- mix+laboratory and expanded case-
mix+laboratory+thyroid medication covariates, but remained statistically significant. 
Similarly, in analyses of time-dependent thyroid status, TSH levels >5.0 and <0.5mIU/L 
were each associated with higher mortality risk across all levels of adjustment (Figure 1B 
and eTable 2).
In sensitivity analyses of baseline TSH that included a 30-day lag period, we observed a 
robust association of TSH levels >5.0 and <0.5mIU/L with higher mortality risk in expanded 
case-mix models (reference: euthyroidism): aHRs (95%CI) 1.17 (1.13-1.22) and 1.17 
(1.14-1.21), respectively (eFigure 2A and eTable 3). In a subcohort of patients who had a 
baseline TSH in euthyroid range and a subsequent TSH measurement (N=161,802), we 
identified 6,027 and 3,445 patients who had incident hypothyroidism and hyperthyroidism, 
respectively. Sensitivity analyses showed that incident hypothyroidism and incident 
hyperthyroidism were each associated with higher mortality risk in expanded case-mix 
models (reference: euthyroidism): aHRs (95%CI) 1.27 (1.20-1.35) and 1.22 (1.16-1.27), 
respectively (eTable 4).
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Granular Thyrotropin Levels and Mortality—A continuum of TSH increase and 
reduction from the reference range is recognized, with early or subclinical disease defined 
by an abnormal TSH with a reference range serum free thyroxine (FT4) measurement, 
which were not available for our study. In analyses that more granularly examined baseline 
TSH levels, we found that TSH categories ≥3.0mIU/L were associated with incrementally 
higher death risk in expanded case-mix models (reference: low- normal TSH): aHRs 
(95%CI) 1.04 (1.02-1.06), 1.15 (1.11-1.18), and 1.38 (1.31-1.46) for TSH levels in the 
upper-normal, subclinical-hypothyroid range, and overt-hypothyroid range, respectively 
(eFigure 3A and eTable 5). These patterns of association persisted in analyses adjusted for 
expanded case-mix+laboratory and expanded case-mix+laboratory+thyroid medication 
covariates. We also observed that TSH categories <0.5mIU/L were associated with higher 
mortality risk in expanded case-mix analyses: aHRs (95%CI) 1.21 (1.16-1.26) and 1.13 
(1.02-1.25) for TSH levels in the subclinical-hyperthyroid and overt-hyperthyroid range. 
Associations between subclinical-hyperthyroid range TSH levels and mortality persisted in 
expanded case-mix+laboratory and expanded case-mix+laboratory+thyroid medication 
analyses. Similar associations were observed in analyses of baseline TSH that included a 30-
day lag period (eFigure 2B and eTable 3).
In analyses of time-dependent TSH levels adjusted for expanded case-mix covariates, we 
analogously observed that TSH categories ≥3.0mIU/L were associated with increasingly 
higher mortality (reference: low-normal TSH): aHRs (95%CI) 1.05 (1.03-1.07), 1.34 
(1.30-1.38), and 1.87 (1.76-1.99) for TSH levels in the upper-normal, subclinical-
hypothyroid range, and overt- hypothyroid range, respectively (eFigure 3B and eTable 5). 
Associations remained significant in expanded case-mix+laboratory and expanded case-mix
+laboratory+thyroid medication adjusted analyses. We similarly observed that TSH levels in 
the subclinical-hyperthyroid and overt-hyperthyroid range were associated with higher 
mortality: aHRs (95%CI) 1.27 (1.22-1.32) and 1.13 (1.02-1.25), respectively. Associations 
between subclinical-hyperthyroid and overt- hyperthyroid range TSH levels and mortality 
persisted in expanded case-mix+laboratory+thyroid medication analyses (eFigure 3B and 
eTable 5).
In sensitivity analyses of baseline and time-dependent TSH as continuous predictors of 
mortality using restricted cubic splines adjusted for expanded case-mix covariates, we 
observed a U-shaped association between TSH level and mortality, with a nadir of risk 
observed at TSH levels ~1.7-2.1mIU/L (Figure 2).
Adjustment for Quality of Care Indicators—To account differential quality of care as 
a potential confounder of thyroid status— mortality associations, in sensitivity analyses we 
also examined several models that incrementally adjusted for proxies of provider 
attentiveness/adherence with health care recommendations and patient medical compliance, 
in addition to expanded case-mix+ laboratory+thyroid medication covariates. Similar to 
expanded case-mix+laboratory+thyroid medication models, we observed that baseline and 
time-dependent TSH levels >5.0 and <0.5mIU/L were each associated with higher mortality 
risk in analyses that incrementally adjusted for ACEi/ARB or statin use, receipt of the 
influenza vaccination, and history of noncompliance (eTable 6).
Rhee et al. Page 7
Mayo Clin Proc. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Following incremental adjustment for these quality of care indicators, we also found that 
associations of baseline TSH levels in the upper-normal, subclinical-hypothyroid, overt- 
hypothyroid, and subclinical hyperthyroid ranges with mortality risk remained robust 
(eTable 7). Following incremental adjustment for ACEi/ARB or statin use, receipt of the 
influenza vaccination, and history of noncompliance, time-dependent TSH levels in the 
upper-normal, subclinical-hypothyroid, overt-hypothyroid, and subclinical hyperthyroid 
ranges, as well as in the overt hyperthyroid range, were associated with higher mortality 
risk, similar to expanded case-mix+laboratory+thyroid medication covariates.
Thyroid Status and Mortality Across Clinically Relevant Subgroups—We also 
examined the association between thyroid status (categorized as TSH >5.0, 0.5- 5.0 
[euthyroidism], and <0.5mIU/L; reference: euthyroidism) and mortality across clinically 
relevant subgroups. In baseline analyses adjusted for expanded case-mix covariates, we 
observed that hypothyroidism was associated with higher mortality across all subgroups 
except those who were female, and that hyperthyroidism was associated with higher 
mortality across all subgroups (Figure 3A and eTable 8). Interaction tests demonstrated that 
differences in estimates of the thyroid function—mortality association across subcategories 
were statistically significant for subgroups of underlying cardiovascular disease and body 
mass index (BMI) (p-interactions=.03 and .05, respectively; Figure 3A). In these analyses, 
we observed that point estimates of the hypothyroidism—mortality association were 
stronger among those without vs. with underlying cardiovascular disease and higher 
(≥25kg/m2) vs. lower BMI (<25kg/m2), and that stronger point estimates of the 
hyperthyroidism—mortality association were also observed among those with higher vs. 
lower BMI.
In time-dependent analyses, we similarly observed that hypothyroidism was associated with 
higher mortality across all subgroups except those who were female, and that 
hyperthyroidism was associated with higher mortality across all subgroups (Figure 3B and 
eTable 9). Interaction tests demonstrated that differences in estimates of the thyroid function
— mortality association across subcategories were statistically significant for subgroups of 
age, race, underlying CHF, and BMI (p-interactions=<.001, <.001, .05, and .04, respectively; 
Figure 3B), with stronger point estimates of hypothyroidism—mortality among those of 
younger (<60 years) vs. older (≥60 years) age, Black vs. non-Black race, with vs. without 
CHF, and higher vs. lower BMI, while stronger point estimates of the hyperthyroidism—
mortality association were observed among those of younger vs. older age, non-Black vs. 
Black race, with vs. without CHF, and higher vs. lower BMI.
Thyroid Status, Medication Use, and Mortality—In the overall cohort, 6.0% and 
<0.1% of patients were prescribed thyroid hormone supplementation or anti-thyroid 
medication at the time of study entry. In baseline analyses adjusted for expanded case-mix 
covariates, we observed that presumed untreated and undertreated hypothyroidism as well as 
untreated hyperthyroidism were associated with higher mortality risk (reference: 
spontaneous euthyroidism): aHRs (95% CI) 1.20 (1.16-1.24), 1.13 (1.07-1.20), and 1.23 
(1.18-1.28), respectively (Figures 4A–B and eTable 10). In time- dependent analyses, the 
same patterns of association were observed. In addition, hypothyroidism treated-to-target 
Rhee et al. Page 8
Mayo Clin Proc. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
TSH range was associated with lower mortality risk (aHR [95%CI] 0.88 [0.85-0.91]) 
(Figures 4C–D and eTable 10).
Discussion
To our knowledge, this is the first study that has examined the association between thyroid 
status defined by repeated measures of serum TSH with mortality in NDD-CKD patients. 
Among a large national cohort of US veterans with Stage 3 CKD, granular examination of 
thyroid status showed that TSH levels in the high-normal (TSH ≥3.0mIU/L) and 
hyperthyroid ranges (TSH <0.5mIU/L) were independently associated with higher mortality 
risk. These associations persisted across multiple secondary and sensitivity analyses that 
considered baseline and time-dependent (i.e., repeated) TSH measures (as a proxy of long-
term and short-term associations, respectively); incrementally adjusted for potential 
confounders of the thyroid status—mortality associations across multivariable models, 
including quality of care indicators (e.g., ACEi/ARB or statin use, receipt of the influenza 
vaccination, history of noncompliance); and examined multiple clinically relevant 
subgroups. In sensitivity analyses that identified cases of incident thyroid disease, we also 
observed that TSH levels in the hypothyroid and hyperthyroid range were each associated 
with higher mortality risk.
Our study also adds new knowledge to the field regarding the impact of thyroid- modulating 
therapy upon the survival of kidney disease patients. While United States Renal Data System 
data show that levothyroxine is one of the most commonly prescribed medications among 
NDD-CKD and ESRD Medicare Part D beneficiaries,36 there have been a paucity of studies 
examining the efficacy and safety of thyroid hormone replacement therapy in these 
populations. In a study of 2,715 dialysis patients whose TSH levels and medication status 
were concurrently examined at study entry, we found patients who were presumed to be 
hypothyroid treated-to-target had similar mortality vs. patients who were spontaneously 
euthyroid, whereas those with undertreated or untreated hypothyroidism had higher 
mortality risk.20 While these limited data suggest benefit, thyroid hormone supplementation 
is a therapy that carries risk, given its 1) narrow toxic-to-therapeutic window,37 2) 
augmentation of protein catabolism and protein-energy wasting38 (i.e., one of the strongest 
death predictors in advanced CKD patients39), and 3) potential to precipitate adverse 
cardiovascular sequelae (e.g., atrial fibrillation, angina) with overtreatment.18,40 Using the 
national VA database with exceptional capture of prescription dispensation data over time,29 
in both baseline and time-dependent analyses we found that untreated and undertreated 
hypothyroidism and untreated hyperthyroidism were each associated with higher mortality 
risk compared to spontaneous euthyroidism, whereas hypothyroidism treated-to-target (i.e., 
TSH 0.5-5.0mIU/L based on general population thresholds17) had similar to slightly lower 
mortality risk. In time-dependent analyses, there also appeared to be a trend between 
overtreated hypothyroidism and lower mortality risk, although only marginally decreased. 
While mild medication-induced thyrotoxicosis may be tolerated in the short-term in 
particular patient groups (i.e., younger patients), further studies are needed to determine the 
long- term safety and effectiveness of thyroid-modulating therapy and specific TSH 
treatment targets.
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As another noteworthy finding, our categorical analyses showed that incrementally higher 
TSH levels even in the high-normal range (TSH ≥3.0mIU/L) were associated with 
increasingly higher mortality risk. Several other studies have similarly shown that TSH 
levels exceeding 3.0mIU/L are associated with higher mortality in dialysis patients.8,20 Even 
in the general population, there remains considerable controversy regarding the optimal 
upper limit of the target TSH range. While some experts recommend a therapeutic TSH 
upper limit of 2.5-3.0mIU/L,19,41,42 others favor using upper TSH laboratory reference 
range values (~5.0mIU/L).43,44 Given the potential risks of under- and overtreatment, 
rigorous prospective studies are warranted determine the optimal TSH target range in the 
CKD and ESRD populations.
While thyroid dysfunction was linked with higher death risk across almost all subgroups, it 
bears mention that stronger hypothyroidism—mortality associations were particularly 
observed among subgroups of younger vs. older age, Black vs. non-Black race, and those 
with vs. without underlying CHF, corroborating emerging data in the general population.45 
As some experts advise that the “normal” range of may differ according to age and race/
ethnicity,46 future studies are needed to more precisely define the ideal TSH thresholds 
among these CKD subgroups. Indeed, the increase in the upper reference for serum TSH 
with age may be especially relevant in the older NDD-CKD population, as most now 
recommend targeting a higher TSH for the elderly general population on levothyroxine 
therapy.44 Furthermore, prior studies in the general population have suggested that those 
with CHF may have lower reserve with which to tolerate hemodynamic, volume, and 
electrophysiologic changes associated with hypothyroidism. Hence, NDD-CKD patients 
with structural heart disease may be particularly vulnerable to the ill effects of 
hypothyroidism, and future studies are needed to determine the specific mechanistic 
pathways linking thyroid perturbations and death in this population.
The strengths of our study include its examination of a large national cohort of NDD- CKD 
patients with comprehensive availability of detailed patient-level information, including 
longitudinal laboratory and prescription data; a stable study population to examine the long-
term and short-term associations of thyroid status, thyroid-modulating therapy, and 
outcomes; and reduced confounding by differential health care access. Several limitations of 
our study should be acknowledged. First, the indications for TSH testing in this cohort, a 
requirement for inclusion in the study, are unknown. However, this inclusion criterion was 
required of all patients irrespective of underlying thyroid status and thus should not impair 
the study’s internal validity. Furthermore, that the vast majority of our source population 
(82.3% of >3.5million patients) underwent TSH testing provides further reassurance 
regarding the study’s external validity. Second, the categories of thyroid status are generally 
classified based on serum TSH and FT4 measurements. Given the sparsity of concurrent 
FT4 and free triiodothyronine (T3) measurements and their unclear reliability in advanced 
CKD (i.e., peripheral conversion of T4- to-T3 is sensitive to non-thyroidal illness; routinely 
used FT4 assays are dependent upon protein- hormone binding, and the presence of uremic 
toxins that interfere with protein-hormone binding may lead to spurious levels),1,2,47-49 we 
elected to define thyroid status based on TSH levels only. Although some aberrations of 
TSH have been described in the context of CKD,50,51 it remains a more robust metric of 
thyroid status particularly in the setting of underlying illness (i.e., TSH levels typically 
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remain normal in mild-moderate non-thyroidal illness, and become suppressed only in 
severe critically illness states1,2,52), and serum TSH has been strongly associated with 
outcomes in our previous studies of dialysis patients,.8,9,20,21 Additionally, we observed 
persistent associations between TSH alterations and mortality in sensitivity analyses that 
incorporated a 30- day lag period and restricted analyses to incident cases of thyroid disease, 
hence excluding patients who died immediately after TSH measurement to minimize risk of 
observing a reverse- causal association (i.e., severe illness may lead to TSH alterations as 
well as heightened mortality risk). Third, as our analyses included patients who were both 
incident (i.e., treatment- naïve) and prevalent (i.e., existing) users of thyroid hormone 
supplementation and anti-thyroid medications, we cannot exclude potential bias towards a 
protective effect of thyroid-modulating therapy (i.e., patients receiving treatment at study 
entry may have been healthier than those who stopped or died using treatment prior to study 
entry due to adverse effects).53 Fourth, given the retrospective nature of the study, we are not 
able to determine whether differential quality of care by providers or non-compliance with 
medical treatment may be a potential confounder of aberrant thyroid status and death risk. 
However, it should be noted that we observed robust thyroid status—mortality associations 
following incremental adjustment for proxies of quality of care. Lastly, as with all 
observational studies, we cannot exclude the possibility of residual confounding, and our 
findings do not confirm a causal relationship between thyroid status, thyroid modulating 
therapy, and mortality risk.
Conclusion
In conclusion, our study has found that higher TSH levels even in the high-normal range 
(≥3.0mIU/L) and lower TSH levels <0.5mIU/L were independently associated with higher 
mortality risk in a national cohort of NDD-CKD patients. We also observed that untreated 
and undertreated hypothyroidism and hyperthyroidism were associated with higher mortality 
compared with spontaneous euthyroidism, whereas hypothyroidism treated-to-target was 
associated with similar to slightly improved survival. At this time, rigorous prospective 
studies are needed to determine the precise optimal TSH range in NDD-CKD patients, and 
whether treatment to these targets ameliorates mortality risk in this population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Portions of these data have been presented as an oral abstract at the 2016 American Society of Nephrology Kidney 
Week Meeting, November 16-20, 2016, Chicago, IL.
Funding Source:
The authors are supported by the research grants from the NIH/NIDDK including K23- DK102903 (CMR), R03-
DK114642 (CMR), R01-DK096920 (CPK, KKZ), K24-DK091419 (KKZ), R01-DK092232 (DVN), and U01-
DK102163 (KKZ, CPK), as well as the American Thyroid Association (CMR) and National Kidney Foundation 
(CMR). The funding organizations/sponsors did not participate in the study design; collection, analysis, and 
interpretation of the data; in the writing of the report; nor in the decision to submit the manuscript for publication.
Rhee et al. Page 11
Mayo Clin Proc. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
List of Abbreviations
4D Trial Die Deutsche Diabetes Dialyse Studie (4D Trial)
ACEi angiotensin converting enzyme inhibitor
ARB angiotensin receptor blocker
BMI body mass index
CCI Charlson Comorbidity Index
CHF congestive heart failure
CKD chronic kidney disease
CVD cerebrovascular disease
DSS-NDE Decision Support System National Data Extracts
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
FT4 free thyroxine
LDL low-density lipoprotein
MICS malnutrition-inflammation-cachexia syndrome
NDD-CKD non-dialysis dependent chronic kidney disease
RCAV Racial and Cardiovascular Risk Anomalies in Chronic Kidney Disease
TSH thyrotropin
T3 triiodothyronine
VA Veterans Affairs
References
1. Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr 
Opin Endocrinol Diabetes Obes. 2016; 23(5):407–415. [PubMed: 27428519] 
2. Rhee CM, Brent GA, Kovesdy CP, et al. Thyroid functional disease: an under-recognized 
cardiovascular risk factor in kidney disease patients. Nephrol Dial Transplant. 2015; 30(5):724–737. 
[PubMed: 24574542] 
3. Carrero JJ, Qureshi AR, Axelsson J, et al. Clinical and biochemical implications of low thyroid 
hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern 
Med. 2007; 262(6):690–701. [PubMed: 17908160] 
4. Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G. Prevalence of subclinical 
hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3(5):1296–
1300. [PubMed: 18550654] 
5. Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical 
hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005; 67(3):1047–1052. 
[PubMed: 15698444] 
Rhee et al. Page 12
Mayo Clin Proc. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6. Rhee CM, Kalantar-Zadeh K, Streja E, et al. The relationship between thyroid function and 
estimated glomerular filtration rate in patients with chronic kidney disease. Nephrol Dial Transplant. 
2015; 30(2):282–287. [PubMed: 25246335] 
7. Targher G, Chonchol M, Zoppini G, et al. Prevalence of thyroid autoimmunity and subclinical 
hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis. Clin Chem 
Lab Med. 2009; 47(11):1367–1371. [PubMed: 19769543] 
8. Rhee CM, Kim S, Gillen DL, et al. Association of thyroid functional disease with mortality in a 
national cohort of incident hemodialysis patients. J Clin Endocrinol Metab. 2015; 100(4):1386–
1395. [PubMed: 25632971] 
9. Rhee CM, Ravel VA, Streja E, et al. Thyroid Functional Disease and Mortality in a National 
Peritoneal Dialysis Cohort. J Clin Endocrinol Metab. 2016; 101(11):4054–4061. [PubMed: 
27525529] 
10. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism 
is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the 
Rotterdam Study. Ann Intern Med. 2000; 132(4):270–278. [PubMed: 10681281] 
11. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007; 116(15):1725–1735. [PubMed: 
17923583] 
12. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001; 344(7):
501–509. [PubMed: 11172193] 
13. Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in 
subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 
2003; 88(8):3731–3737. [PubMed: 12915662] 
14. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure 
events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012; 
126(9):1040–1049. [PubMed: 22821943] 
15. US Renal Data SystemUSRDS 2016 Annual Data Report: Atlas of End-Stage Renal Disease in the 
United States Bethesda, MD: 2016
16. Saran R, Li Y, Robinson B, et al. US Renal Data System 2015 Annual Data Report: Epidemiology 
of Kidney Disease in the United States. Am J Kidney Dis. 2016; 67(3 Suppl 1):Svii, S1–305.
17. Ladenson PW. Diagnosis of Hypothyroidism In: Braverman LE, Cooper DS, eds Werner and 
Ingbar’s The Thyroid 10th. Philadelphia, PA: Lippincott Williams and Wilkins; 2013 606611
18. Jonklaas J. Treatment of Hypothyroidism In Braverman LE, Cooper DS, eds Werner and Ingbar’s 
The Thyroid 10th. Philadelphia, PA: Lippincott Williams and Wilkins; 2013 611628
19. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory 
support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003; 13(1):3–126. 
[PubMed: 12625976] 
20. Rhee CM, Alexander EK, Bhan I, Brunelli SM. Hypothyroidism and Mortality among Dialysis 
Patients. Clin J Am Soc Nephrol. 2013; 8(4):593–601. [PubMed: 23258793] 
21. Rhee CM, You AS, Nguyen DV, et al. Thyroid Status and Mortality in a Prospective Hemodialysis 
Cohort. J Clin Endocrinol Metab. 2017; 102(5):1568–1577. [PubMed: 28324018] 
22. Drechsler C, Schneider A, Gutjahr-Lengsfeld L, et al. Thyroid function, cardiovascular events, and 
mortality in diabetic hemodialysis patients. Am J Kidney Dis. 2014; 63(6):988–996. [PubMed: 
24315768] 
23. Kovesdy CP, Norris KC, Boulware LE, et al. Association of Race With Mortality and 
Cardiovascular Events in a Large Cohort of US Veterans. Circulation. 2015; 132(16):1538–1548. 
[PubMed: 26384521] 
24. Lu JL, Molnar MZ, Naseer A, Mikkelsen MK, Kalantar-Zadeh K, Kovesdy CP. Association of age 
and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol. 2015; 
3(9):704–714. [PubMed: 26235959] 
25. Molnar MZ, Kalantar-Zadeh K, Lott EH, et al. Angiotensin-converting enzyme inhibitor, 
angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll 
Cardiol. 2014; 63(7):650–658. [PubMed: 24269363] 
Rhee et al. Page 13
Mayo Clin Proc. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
26. Novak M, Mucsi I, Rhee CM, et al. Increased Risk of Incident Chronic Kidney Disease, 
Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression. 
Diabetes Care. 2016; 39(11):1940–1947. [PubMed: 27311494] 
27. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time- dependent 
effects and time-varying risk factors. Kidney Int. 2008; 74(8):994–997. [PubMed: 18633346] 
28. US Department of Veterans Affairs; Health Services Research and Development Service; VA 
Information Resource CenterVIReC Research User Guide: VHA Decision Support System 
Clinical National Data Extracts 2nd. Hines, IL: VA Information Resource Center; 2009
29. US Department of Veterans Affairs; Health Services Research and Development Service; VA 
Information Resource CenterVIReC Research User Guide: VHA Pharmacy Prescription Data 2nd. 
Hines, IL: VA Information Resource Center; 2008
30. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the 
Department of Veterans Affairs. Popul Health Metr. 2006; 4:2. [PubMed: 16606453] 
31. Stroupe KT, Tarlov E, Zhang Q, Haywood T, Owens A, Hynes DM. Use of Medicare and DOD 
data for improving VA race data quality. J Rehabil Res Dev. 2010; 47(8):781–795. [PubMed: 
21110252] 
32. US Department of Veterans Affairs; Health Services Research and Development Service; VA 
Information Resource CenterVIReC Research User Guide: VHA Medical SAS Datasets 
FY2006-2007 Hines, IL: VA Information Resource Center; 2007
33. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM 
administrative databases. J Clin Epidemiol. 1992; 45(6):613–619. [PubMed: 1607900] 
34. US Department of Veterans Affairs; Health Services Research and Development Service; VA 
Information Resource CenterVIReC Resource Guide: VA Corporate Data Warehouse Hines, IL: 
VA Information Resource Center; 2012
35. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. 
Ann Intern Med. 2009; 150(9):604–612. [PubMed: 19414839] 
36. US Renal Data SystemUSRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the 
United States Bethesda, MD: 2012
37. Wartofsky L. Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. 
Expert Opin Pharmacother. 2002; 3(6):727–732. [PubMed: 12036412] 
38. Lim VS. Thyroid function in patients with chronic renal failure. Am J Kidney Dis. 2001; 38(4 
Suppl 1):S80–84. [PubMed: 11576928] 
39. Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP. Why cachexia kills: 
examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle. 
2013; 4(2):89–94. [PubMed: 23749718] 
40. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial 
fibrillation in older persons. N Engl J Med. 1994; 331(19):1249–1252. [PubMed: 7935681] 
41. Baskin HJ, Cobin RH, Duick DS, et al. American Association of Clinical Endocrinologists medical 
guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and 
hypothyroidism. Endocr Pract. 2002; 8(6):457–469.
42. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J 
Clin Endocrinol Metab. 2005; 90(9):5483–5488. [PubMed: 16148345] 
43. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: 
cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid 
Association. Thyroid. 2012; 22(12):1200–1235. [PubMed: 22954017] 
44. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared 
by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 
24(12):1670–1751. [PubMed: 25266247] 
45. Rhee CM, Curhan GC, Alexander EK, Bhan I, Brunelli SM. Subclinical hypothyroidism and 
survival: the effects of heart failure and race. J Clin Endocrinol Metab. 2013; 98(6):2326–2336. 
[PubMed: 23720788] 
46. Surks MI, Boucai L. Age- and race-based serum thyrotropin reference limits. J Clin Endocrinol 
Metab. 2010; 95(2):496–502. [PubMed: 19965925] 
Rhee et al. Page 14
Mayo Clin Proc. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
47. Soldin OP. Measuring serum thyroid-stimulating hormone, thyroid hormones, thyroid- directed 
antibodies, and transport proteins. In: Braverman LE, , Cooper DS, editorsWerner and Ingbar’s 
The Thyroid 10th. Philadelphia, PA: Lippincott Williams and Wilkins; 2013 279297
48. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr 
Rev. 1996; 17(1):45–63. [PubMed: 8641223] 
49. Langton JE, Brent GA. Nonthyroidal illness syndrome: evaluation of thyroid function in sick 
patients. Endocrinol Metab Clin North Am. 2002; 31(1):159–172. [PubMed: 12055987] 
50. Carrero JJ, , Stenvinkel P, , Lindholm B. Endocrine Aspects of Chronic Kidney Disease. In: Taal 
MW, Chertow GM, Marsden PA, Skorecki K, Yu AS, , Brenner BM, editorsTaal: Brenner and 
Rector’s The Kidney 9th. Philadelphia, PA: Elsevier Saunders; 2012 21222137
51. Kaptein EM, LoPresti JS, Kaptein MJ. Is an isolated TSH elevation in chronic nonthyroidal illness 
“subclinical hypothyroidism”? J Clin Endocrinol Metab. 2014; 99(11):4015–4026. [PubMed: 
25166720] 
52. Wiersinga WM, , Van den Berghe G. Nonthyroidal Illness Syndrome. In: Braverman LE, , Cooper 
DS, editorsWerner and Ingbar’s The Thyroid 10th. Philadelphia, PA: Lippincott Williams and 
Wilkins; 2013 203216
53. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J 
Epidemiol. 2003; 158(9):915–920. [PubMed: 14585769] 
Rhee et al. Page 15
Mayo Clin Proc. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Association between baseline (Panel A) and time-dependent (Panel B) thyroid status 
and all-cause mortality
Unadjusted model included serum TSH level. Case-mix model adjusted for covariates in the 
unadjusted model, as well as age, sex, race, and ethnicity. Expanded case-mix model 
adjusted for covariates in the case-mix model, as well as diabetes, congestive heart failure, 
cardiovascular disease, hypertension, hyperlipidemia, and Charlson Comorbidity Index. 
Expanded case-mix+laboratory model adjusted for covariates in the expanded case-mix 
model, as well as estimated glomerular filtration rate, serum albumin, hemoglobin, 
cholesterol, triglycerides, low-density lipoprotein. Expanded case-mix+laboratory+thyroid 
medication model adjusted for covariates in the expanded case-mix+laboratory model, as 
well as thyroid hormone supplementation and anti-thyroid medication use.
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Figure 2. Association between continuous baseline (Panel A) and time-dependent (Panel B) 
thyrotropin (TSH) and all-cause mortality
Figures present hazard ratios (short-dashed line) and 95%CI’s (solid lines) for TSH analyzed 
as a spline with knots at the 33rd and 66th percentiles of observed values (TSH levels 
1.4mIU/L and 2.4mIU/L, respectively). A histogram of observed TSH values and a hazard 
reference ratio of 1 (dashed line) is overlaid. Analyses shown are expanded case-mix 
adjusted models, which included serum TSH level, age, sex, race, ethnicity, diabetes, 
congestive heart failure, cardiovascular disease, hypertension, hyperlipidemia, and Charlson 
Comorbidity Index.
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Figure 3. Baseline (Panel A) and time-dependent (Panel B) thyroid status and all-cause mortality 
across clinically relevant subgroups
P-values for interaction tests presented. Analyses shown are expanded case-mix adjusted 
models, which included serum TSH level, age, sex, race, ethnicity, diabetes, congestive heart 
failure, cardiovascular disease, hypertension, hyperlipidemia, and Charlson Comorbidity 
Index. Abbreviations: eGFR, estimated glomerular filtration rate; CHF, congestive heart 
failure; CVD, cardiovascular disease; BMI, body mass index.
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Figure 4. Baseline (Panels A and B) and time-dependent (Panels C and D) thyroid status, thyroid 
medications, and all-cause mortality
Analyses shown are expanded case-mix adjusted models, which included serum TSH level, 
age, sex, race, ethnicity, diabetes, congestive heart failure, cardiovascular disease, 
hypertension, hyperlipidemia, and Charlson Comorbidity Index.
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